ArticleFrontiers in immunology2025
Tertiary lymphoid structures correlate with the therapeutic efficacy and prognosis of resectable esophageal squamous cell carcinoma undergoing neoadjuvant chemoradiotherapy plus immunotherapy.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Immunogenic cell death and tertiary lymphoid structures: bridging tumour cell death and immune organization.Nature reviews. Immunology · 2026Review
- Review
- Prognostic value of tertiary lymphoid structures in high-risk esophageal squamous cell carcinoma following neoadjuvant chemoimmunotherapy.BMC cancer · 2026Article
- Tertiary lymphoid structures predict outcomes of neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma.BMC cancer · 2026Article
- Tertiary lymphoid structures in neoadjuvant and perioperative cancer immunotherapy: a review and proposed framework for biomarker interpretation and validation.Frontiers in immunology · 2026Review
- Mechanistic roles and clinical applications of tertiary lymphoid structures in colorectal cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2026Review
- Immunotherapy resistance and strategies in malignant pleural mesothelioma.Cancer drug resistance (Alhambra, Calif.) · 2026Review
- Clinical and prognostic significance of high-endothelial venule density in regional lymph nodes of esophageal adenocarcinoma.Frontiers in oncology · 2026Article
- Residual pattern of primary tumor and lymph node in ESCC treated with nCRT with or without pembrolizumab: an analysis from a prospective cohort.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tertiary lymphoid structures (TLSs) are linked to prognosis in esophageal squamous cell carcinoma (ESCC), but whether the distribution, abundance, and maturity of TLSs affect therapeutic efficacy and prognosis in ESCC treated with neoadjuvant chemoradiotherapy plus immunotherapy (NRCI) remains unclear. We explored TLS characteristics and correlated them with patient survival. Methods: A total of 157 resectable ESCC patients treated with neoadjuvant therapy between September 2020 and May 2023 were divided into NRCI (n=49) and neoadjuvant chemoimmunotherapy (NCI, n=108) groups. Multiplex immunofluorescence (mIHC) was employed to compare the spatial distribution and cellular composition of TLSs in the NRCI (n=40) and NCI (n=40) groups. A TLSs scoring system assessed TLSs abundance and maturity across intratumoral regions (T regions), invasive margins (IM regions), and peritumoral regions (P regions). The differences in overall survival (OS) and disease-free survival (DFS) between the two groups were analyzed. Furthermore, whole-exome sequencing (WES) on 20 untreated ESCC samples examined the relationship between TLS infiltration and genetic mutations. Results: The OS and DFS in the NRCI group were significantly superior to the NCI group, with a higher rate of major pathological response (MPR). MPR patients exhibited significantly longer OS and DFS, suggesting that NRCI therapy substantially enhanced patient outcomes (all Conclusion: NRCI therapy significantly enhanced the prognosis of resectable ESCCs compared to NCI therapy. The distribution and abundance of TLSs were clearly associated with OS in ESCCs and acted as independent prognostic indicators for OS in NRCI therapy. NRCI therapy extended OS and bolstered antitumor immune responses by facilitating the proliferation and activation of M-TLSs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.